KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:开放图源暂不可得 入排置信度 0.98

Final overall survival analysis of the APPLE study: atezolizumab and platinum-pemetrexed with or without bevacizumab for metastatic nonsquamous non-small cell lung cancer.

Yoshimasa Shiraishi, Junji Kishimoto, Shunichi Sugawara, Hideaki Mizutani, Haruko Daga, Koichi Azuma, Hirotaka Matsumoto, Osamu Hataji, Kazumi Nishino, Masahide Mori, Takehito Shukuya, Haruhiro Saito, Motoko Tachihara, Kaoru Tanaka, Asuka Tsuya, Kazushige Wakuda, Noriko Yanagitani, Tomohiro Sakamoto, Junko Baba, Akito Hata, Morihito Okada, Toshiyuki Kozuki, Yuki Sato, Yuriko Takahata, Tadaaki Yamada, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Isamu Okamoto

Lung Cancer 217 109447

PMID42127535
PMCID-
DOI10.1016/j.lungcan.2026.109447
发表日期2026-05-13
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND: The phase III APPLE trial evaluated the efficacy of adding bevacizumab to atezolizumab with carboplatin plus pemetrexed (APP) for individuals with advanced nonsquamous non-small cell lung cancer (NSCLC). We here report the long-term outcomes of this trial with 3.5 years of follow-up. METHODS: Patients with advanced nonsquamous NSCLC were randomized 1:1 to receive APP or APP plus bevacizumab (APPB). Stratification factors were clinical stage, driver oncogenes, and PD-L1 expression. Endpoints included progression-free survival, overall survival (OS), and safety. RESULTS: A total of 412 patients were enrolled; 1 patient was excluded from the intention-to-treat population. Of the remaining patients, 287 patients were classified as driver oncogene-negative and 124 as driver oncogene-positive. The updated median OS was 28.0 months in the APPB arm and 25.7 months in the APP arm, with a hazard ratio (HR) of 0.88 (95% confidence interval [CI], 0.70-1.10). For the driver oncogene-negative population, the median OS was 27.6 months in the APPB arm and 27.8 months in the APP arm (HR of 0.96 [95% CI, 0.73-1.27]), with the corresponding values for the driver oncogene-positive population being 28.0 and 20.8 months (HR of 0.71 [95% CI, 0.47-1.08]). Safety profiles did not change from earlier analysis. CONCLUSIONS: The addition of bevacizumab to APP did not improve OS in patients with advanced nonsquamous NSCLC. In the driver oncogene-positive subgroup, favorable OS trend was observed in the bevacizumab arm, highlighting its potential as a treatment option for individuals who have failed molecular-targeted therapy.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。